Peregrine Sued By Investors Over Cancer Drug Claims
Investors hit Peregrine Pharmaceuticals Inc. with multiple securities class actions last month, alleging that the drugmaker's misleading statements about its lung cancer drug later resulted in a nosedive of the company's...To view the full article, register now.
Already a subscriber? Click here to view full article